1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Wet Age-Related Macular Degeneration - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 Wet Age-Related Macular Degeneration - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Wet Age-Related Macular Degeneration - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 Wet Age-Related Macular Degeneration - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Wet Age-Related Macular Degeneration Guidelines, Management and Treatment
8.2 Wet Age-Related Macular Degeneration Treatment Algorithm
9 Wet Age-Related Macular Degeneration - Unmet Needs
10 Wet Age-Related Macular Degeneration - Key Endpoints of Treatment
11 Wet Age-Related Macular Degeneration - Marketed Products
11.1 List of Wet Age-Related Macular Degeneration Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Wet Age-Related Macular Degeneration - Pipeline Drugs
12.1 List of Wet Age-Related Macular Degeneration Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Wet Age-Related Macular Degeneration - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Wet Age-Related Macular Degeneration - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Wet Age-Related Macular Degeneration - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Wet Age-Related Macular Degeneration - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Wet Age-Related Macular Degeneration - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Wet Age-Related Macular Degeneration - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Wet Age-Related Macular Degeneration - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Wet Age-Related Macular Degeneration - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Wet Age-Related Macular Degeneration - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Wet Age-Related Macular Degeneration - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Wet Age-Related Macular Degeneration - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Wet Age-Related Macular Degeneration - Access and Reimbursement Overview
15 Wet Age-Related Macular Degeneration - Recent Events and Inputs From Key Opinion Leaders
16 Wet Age-Related Macular Degeneration Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 Appendix